Samchondang Pharmaceutical Co., Ltd

Samchondang Pharmaceutical Co., Ltd

- Stocks with a lot of credit and stocks with a lot of individuals always show a pattern of shaking off the volume before sending the stock price. Recent examples include HLB and Alteogen

- On the same day, the disclosure team will have checked the contents, and the information must have leaked first because it is a stock that many straws selected, and the pattern of shaking off the volume as reverse information is sensitive to bad news

- Last year, all bio stocks were not interested in the market, so if it was an individual stock material, HLB and Alteogen are showing a spectacular rise in stock prices and looking for late-stage bio stocks

- The only way to put all the good antics to sleep at once is to disclose the contract. If the contract came out, there is no logic to dismiss it. If you think about it, you're keeping everything you've been communicating with the market

- Even this contract is not the last boon, the largest contract size in the U.S. is also expected to be in the second quarter, which is just around the corner, and the unveiling of the global partner of Espass remains

- Stock price performance varies depending on the strength of the sector's stock price. HLB highlights the relative price advantage over Alteogen, and suggests a place to go to FOMO, which was unable to board HLB and Alteogen

- EPS is determined by the company, but multiplexing is determined by the market situation at the time. It is a situation where there is an environment in which multiplexing is more advantageous than last year, and there is no short sale in the simultaneous upward section of estimated EPS and multiplexing

Why This Time Is Expected to Show a Different Trend